Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis ...Middle East

Oral PL8177 may provide a safe, effective, and tolerable treatment option for ulcerative colitis patients prior to immunosuppressive therapies and steroid treatments, which have significant safety and tolerability concerns Preclinical data demonstrated that oral PL8177 caused diseased...

Hence then, the article about palatin announces completion of patient enrollment in phase 2 study of orally administered melanocortin agonist pl8177 in ulcerative colitis was published today ( Monday 25/11/2024 - 03:36 PM ) and is available on PR Newswire ( Middle East ) The editorial team at PressBee has edited and verified it, and it may have been modified, fully republished, or quoted. You can read and follow the updates of this news or article from its original source.

Read More Details
Finally We wish PressBee provided you with enough information of ( Palatin Announces Completion of Patient Enrollment in Phase 2 Study of Orally Administered Melanocortin Agonist PL8177 in Ulcerative Colitis )

Also on site :

• Exclusive: Anthropic acknowledges testing new AI model representing ‘step change’ in capabilities, after accidental data leak reveals its existence
• Retired Gen. Wesley Clark tangled up in a crypto fraud suit with Burning Man buddies
• 1965 Timeless Classic Ranked Among ‘Greatest Country Songs of All Time’ Became a Long-Running No. 1 Hit